A $25M Seed Round! Ex-BioNTech Execs Build Cancer Digital Twins | Bios Life

Bios Life just raised $25M to build cancer digital twins for 40 million high-risk individuals. Their founding team? Former BioNTech executives who already built and sold a company for nearly $700 million.

Chapters:

0:00 Intro - The $25M Seed Round

0:54 Dream Team Founders

1:50 The Nucleotide Transformer Tech

2:33 Why This Business Model Works

3:59 The Data Moat

5:42 Lightning Round

7:08 Key Takeaways

In this episode we break down:

• How Ryan Richardson (ex-BioNTech CSO) and Zack Taylor built their founding team
• The nucleotide transformer that reads genetic data at single nucleotide resolution
• Why they're building a SaaS-like subscription instead of one-off screening tests
• Their virtual care network that creates a real competitive moat
• The Tempus alliance and exclusive nucleotide transformer license
• What investors Red Mile, V-squared, and Kindred Capital are betting on

Bios Life isn't just selling a test - they're building continuous health monitoring for people who desperately need it.